Lifecore Biomedical, Inc.
corporate_fare Company Profile
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LFCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for LFCR spans 8-K, PREM14A, SCHEDULE 13D/A, DEFA14A.
Recent high-impact activity:
- Lifecore Q3 Revenue Falls 18.6% to $25.3M; $40.1M Net Loss Driven by Non-Cash Derivative Mark
- Lifecore Proxy Sets Vote on $6.28 Cash Takeover; Go-Shop Ends With No Rival Bid
- Wynnefield Locks Up 14.3% Stake Behind Webster Acquisition
- Legion Partners Locks Up 17.3% Stake in Support of Webster Equity Merger
- Lifecore Locks Up Activist Holders and Extends Alcon Deal in $6.28/Share Webster Buyout
Financial Snapshot
Short Interest & Short Volume
3.52 days to coverFINRA reported short interest of 1,722,308 shares in LFCR as of the October 30, 2026 settlement, a 4.5% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 38.3% of LFCR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LFCR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
New Stock Incentive Plan Approved · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →